Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors

Documenti analoghi

• A quantitative model‐based approach for adavosertib dose selection in patients with uterine serous carcinoma
  di: Shankar Lanke, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC
  di: Jincheng Yang, et al.
  Pubblicazione: (2025)
• Reply to “High Pharmacokinetic Variability and Unrecognized Limitations in First‐Line Osimertinib Plus Chemotherapy for EGFR ‐Mutated NSCLC ”
  di: Azar Shahraz, et al.
  Pubblicazione: (2025)
• External Evaluation of Population Pharmacokinetic Models for High‐Dose Methotrexate in Adult Patients with Hematological Tumors
  di: Shengyang Chen, et al.
  Pubblicazione: (2024)
• Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103)
  di: Elena Garralda, et al.
  Pubblicazione: (2024)